Suppr超能文献

相似文献

1
Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective.
AAPS J. 2012 Dec;14(4):749-58. doi: 10.1208/s12248-012-9387-9. Epub 2012 Jul 24.
2
Reporting guidelines for population pharmacokinetic analyses.
J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):301-14. doi: 10.1007/s10928-015-9417-1. Epub 2015 Apr 30.
3
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements.
Drug Discov Today. 2011 Jul;16(13-14):583-93. doi: 10.1016/j.drudis.2011.05.006. Epub 2011 May 24.
6
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
7
The use of population pharmacokinetics in drug development.
Clin Pharmacokinet. 1996 Feb;30(2):81-93. doi: 10.2165/00003088-199630020-00001.
8
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Drug Discov Today. 2017 Oct;22(10):1447-1459. doi: 10.1016/j.drudis.2017.04.015. Epub 2017 May 2.
10
Quality control and assurance from the development to the production of biopharmaceuticals.
Trends Biotechnol. 1999 Jul;17(7):266-70. doi: 10.1016/s0167-7799(99)01314-1.

引用本文的文献

1
The Dietary Biomarkers Development Consortium: An Initiative for Discovery and Validation of Dietary Biomarkers for Precision Nutrition.
Curr Dev Nutr. 2025 Apr 5;9(5):107435. doi: 10.1016/j.cdnut.2025.107435. eCollection 2025 May.
2
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.
Br J Clin Pharmacol. 2025 Apr;91(4):1064-1079. doi: 10.1111/bcp.16335. Epub 2024 Nov 21.
3
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Cancer Chemother Pharmacol. 2024 Sep;94(3):349-360. doi: 10.1007/s00280-024-04679-z. Epub 2024 Jun 15.
4
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1264-1277. doi: 10.1002/psp4.13160. Epub 2024 May 21.
5
Improving pharmacometrics analysis efficiency using DataCheQC: An interactive, Shiny-based app for quality control of pharmacometrics datasets.
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1375-1385. doi: 10.1002/psp4.13017. Epub 2023 Aug 18.
6
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).
CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1187-1200. doi: 10.1002/psp4.13002. Epub 2023 Jun 11.
9
Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout.
Br J Clin Pharmacol. 2022 Dec;88(12):5359-5368. doi: 10.1111/bcp.15462. Epub 2022 Jul 28.
10
Design and conduct considerations for studies in patients with impaired renal function.
Clin Transl Sci. 2021 Sep;14(5):1689-1704. doi: 10.1111/cts.13061. Epub 2021 Jun 25.

本文引用的文献

1
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.
Comput Methods Programs Biomed. 2011 Jan;101(1):72-9. doi: 10.1016/j.cmpb.2010.04.018. Epub 2010 Jun 2.
3
Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.
Br J Clin Pharmacol. 2000 Aug;50(2):135-45. doi: 10.1046/j.1365-2125.2000.00237.x.
4
A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.
J Pharmacokinet Biopharm. 1996 Apr;24(2):153-72. doi: 10.1007/BF02353487.
5
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH).
Br J Clin Pharmacol. 1994 May;37(5):401-4. doi: 10.1111/j.1365-2125.1994.tb05705.x.
6
Validation of simple and complex models in physiology and medicine.
Am J Physiol. 1984 Feb;246(2 Pt 2):R259-66. doi: 10.1152/ajpregu.1984.246.2.R259.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验